TGA finds semaglutide in supposed retatrutide after serious injury report

Australia’s Therapeutic Goods Administration issued a safety advisory September 14 after investigating a product sold as retatrutide that was linked to a serious adverse-event report. Laboratory testing found undeclared semaglutide and no retatrutide, exposing an ingredient substitution in a product marketed for weight loss.

The consumer experienced uncontrollable vomiting, a torn esophagus and hospitalization, according to the regulator. The advisory adds a concrete laboratory finding to concerns about unapproved peptide products: the substance supplied may differ entirely from the drug a buyer believes they are receiving.

What the investigation found

The TGA obtained a sample in its original, unmarked vial. It reported that the amount of semaglutide detected was approximately eight times the level found in semaglutide products assessed by the agency and included in Australia’s register of therapeutic goods.

That comparison describes the tested product. It should not be interpreted as a verified measurement of how much the patient administered. September 14 is the advisory’s publication date; the available account does not establish when the injury occurred.

The finding also limits what can be concluded about retatrutide itself. An adverse event involving a sample with no detectable retatrutide cannot establish the investigational molecule’s safety profile.

A serious signal with limited clinical detail

This is an adverse-event investigation involving a reported patient and a tested product, rather than a controlled clinical study. There is no comparison group or denominator showing how many people used the same product without reporting an injury. The account therefore cannot quantify the incidence of esophageal injury or ingredient substitution across the market.

In ABC News’s September 14 reporting, Melbourne gastroenterologist Darcy Holt explained that severe, forceful vomiting can tear the esophagus. He described the injury as a medical emergency because leakage into the surrounding chest can cause serious infection and inflammation. His comments provide clinical context; they are not an independently published assessment of this patient’s complete medical record.

TGA chief medical advisor Robyn Langham told ABC that uncertainty extends beyond the identity and amount of an ingredient to sterility and possible contaminants. These are broader concerns about unapproved injectable products. The reported laboratory finding does not establish that contamination contributed to this particular injury.

Regulatory status remains separate from marketing

Retatrutide remains investigational. The TGA says it has not been approved by the agency or a comparable international regulator. In the United States, the FDA’s current public guidance likewise states that retatrutide is not an ingredient in an approved medicine and cannot be used in compounding under federal law.

The FDA also distinguishes approved medicines from compounded products, which do not undergo its premarket review for safety, effectiveness and quality. Its guidance describes reports of serious gastrointestinal symptoms and hospitalizations potentially associated with dosing errors or use beyond approved labeling for compounded semaglutide and tirzepatide. Those reports concern separate products and do not establish the cause of the Australian case.

For metabolic-health and peptide medicine, the practical significance is a product-quality failure with potential clinical consequences. Evidence generated for a specified medicine cannot establish the identity, strength or quality of an unrelated vial sold under its name. The new alert supports that distinction directly, while leaving the scale of the substitution problem and the patient’s complete clinical course unresolved.